Professional Advisory Board Statement on the FDA Warning Concerning Fluoroquinolones
In December 2018, the US Food and Drug Administration (FDA) issued a warning against the use of fluoroquinolones in people with Marfan syndrome and other related genetic aortic conditions. The FDA’s warning indicated that fluoroquinolones, a commonly prescribed class of antibiotics that includes Avelox, Cipro, Factive, Levaquin, and Ofloxacin, should not be used in people with certain genetic conditions…